Transcranial Magnetic Stimulation for the Treatment of Major Depression for Florida Blue
Customize your policy alerts
Sign up for lucet Policy 20.5.008 alerts
Get alerted when Policy 20.5.008 changes without checking for updates manually.
Monitor payer policy activity
Defines clinical coverage, authorization requirements, and limitations for TMS treatment of treatment‑resistant major depressive disorder for Florida Blue members; applies to providers requesting TMS benefits under Lucet's administration.
Florida Blue requires age to start at 15 years old.
Coverage Criteria
Initial Authorization
Covered when ALL of the following are met:
All elements (a)–(c) required
Retreatment Authorization
Retreatment covered when ALL of the following are met:
All conditions required
Delivery & Monitoring
Covered when ALL of the following delivery and monitoring expectations are met:
Psychiatrist must perform first session and MT re‑determination
Clinical evidence and administrative constraints
Coverage context and clinical evidence summary from literature (no explicit member-level criteria in this section).
References include meta-analyses and reviews; evidence strength variable [18,20]
Supports potential extended/maintenance protocols [21]
Document history records this administrative change [36]
TMS is considered not medically necessary or inappropriate when any of the following exclusionary clinical contexts apply: active substance abuse, active psychotic symptoms, acute suicidal risk, catatonia, severe life‑threatening dysfunction in basic needs, or an active neurologic disorder (examples include encephalopathy, dementia, Parkinson’s disease, post‑stroke syndromes, increased intracranial pressure or bleeding, cerebral aneurysm, arteriovenous malformation, CSF shunts, or implants in the CNS or head/neck).
Coverage is also excluded for requests that involve non‑TRD psychiatric diagnoses (DSM disorders other than treatment‑resistant major depressive disorder), obsessive–compulsive disorder (OCD), presence of non‑removable metallic objects or implants in the head/neck, Maintenance TMS, Intermittent Theta Burst Stimulation (iTBS), Magnetic Seizure Therapy (MST), and Navigated TMS (nTMS), as these uses are specified as not appropriate in the policy.
Any request that would require an exception to this medical policy must be submitted for review and approved by the Lucet Chief Medical Officer (CMO) or their designee before coverage will be authorized.
Requests for Maintenance TMS, iTBS (intermittent theta burst stimulation), MST (magnetic seizure therapy), nTMS (navigated TMS), and TMS for psychiatric diagnoses other than treatment‑resistant depression (including OCD) are considered not medically necessary under this policy and will not be covered.
The policy review cites systematic reviews and individual studies showing promising symptom reduction with TMS/dTMS across disorders but notes consistent limitations in the evidence base: many studies have small sample sizes, some report mixed results, and prior trials often lack standardized, controlled monitoring of earlier pharmacologic and psychotherapeutic treatments.
Because of these limitations the literature and the policy highlight a need for larger replication trials and long‑term/maintenance studies to better define durability, optimal protocols, and safety across indications.
Coding and Rating Scales
| ICD-10: F32.x, F33.x | Major Depressive Disorder (single and recurrent), without psychosis |
| affected codes | Document references affected codes in relation to prior authorization (no explicit CPT/HCPCS listed in this part of the document). |
Provider Actions & Prior Authorization
Prior Authorization Required
Prior authorization is required for initial TMS/dTMS treatment courses. Requests must include diagnostic confirmation, a baseline clinically accepted depression rating scale score (see Table 1), patient age (15–70), and documentation of prior medication trials or intolerances. Use the Transcranial Magnetic Stimulation (TMS) Request Form when submitting authorization requests.
- Required form: Transcranial Magnetic Stimulation (TMS) Request Form
- Age requirement: 15–70 years
- Required documentation: depression rating scale score (Table 1), diagnosis (ICD-10 F32.x/F33.x), prior treatment history
Prior Treatment History Expected
Prior treatment history must be documented. The request should include details of prior pharmacologic and procedural treatments, including dates, agents, doses, durations, outcomes, and any documented intolerances. Specifically, documentation must show failure of two adequate trials of FDA‑approved antidepressants from at least two different classes (or two trials with documented intolerable side effects), unless the provider documents that TMS is being chosen as a less invasive alternative to ECT or the member declines ECT.
- Failure of two trials from at least two antidepressant classes OR two trials with documented intolerable side effects
- Include dates, doses, duration, and clinical response for each prior trial
- If prior TMS produced response, include prior rating scale showing ≥50% improvement and date of prior treatment termination (≥90 days since termination for retreatment)
Exceptions Require CMO Approval
Exceptions to this policy (including requests that do not meet standard prior authorization criteria) must be submitted for review and require approval by the Lucet Chief Medical Officer (CMO) or their designee. Provide a clear clinical rationale and supporting documentation when requesting an exception.
- All exceptions require Lucet CMO or designee approval
- Include detailed clinical rationale and supporting records with exception requests
- Route exception requests via the TMS Request Form and authorization workflow
Background & Evidence Summary
Transcranial Magnetic Stimulation (TMS) is a noninvasive neuromodulation therapy that uses focused magnetic fields delivered to cortical targets to modulate brain activity; it is used primarily as an adjunctive therapy for treatment‑resistant major depressive disorder and has been studied in disorders such as OCD, PTSD, and anxiety disorders.
Clinical benefits reported in randomized trials and real‑world series include reduction in depressive symptom severity and, in some cases, clinically meaningful response or remission. Common adverse effects are generally mild and transient (for example, scalp discomfort or headache), while procedures such as magnetic seizure therapy carry different risk profiles and are not covered under this policy.
Policy delivery expectations require use of FDA‑cleared devices, an initial psychiatrist‑performed cortical mapping and motor threshold determination, and standardized rating‑scale monitoring during the acute course. The evidence base for some newer protocols (for example, dTMS, iTBS, MST, and nTMS), specific age groups, and maintenance regimens remains variable, which underlies the policy’s focused coverage for conventional rTMS in treatment‑resistant depression and exclusion of certain protocols and indications.
Definitions
Level of Care Criteria
Outpatient
Outpatient TMS is covered when the following level-of-care expectations are met:
Outpatient TMS framework
Monitoring requirement
Treatment Modalities
TMS (rTMS, conventional)
Standard conventional rTMS (repetitive TMS) is covered when the following modality-specific expectations are met:
Standard rTMS covered with criteria
TMS / dTMS
Deep TMS (dTMS) and modality-specific guidance:
Meta-analyses and real-world reports cited
Supports potential extended treatment protocols and maintenance considerations [21]
Visit Limits and Session Scheduling
Revision History
Florida Blue (Lucet) added a minimum age requirement specifying that members must be at least 15 years old to start TMS.
Policy document created/entered as new on 02/2025 by Dr. J. Langlow.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.